In the second quarter of 2026, DENTSPLY SIRONA reported revenue of $898 million. That was down 4.1% year over year, or 6.3% in constant currencies. Revenue came in above the market consensus of roughly $889 million to $890 million, and adjusted earnings per share were $0.52.
For the trailing period, the company recorded a net loss of $546 million, a profit margin of -14.99% and diluted earnings per share of -2.71. Trailing revenue was $3.64 billion.
The listed previous close was 8.44, just above the 52-week low of 8.33. The 52-week high was 14.76. The quoted day's range was 8.49 to 8.61, and the opening price was 8.49. Intraday market capitalisation was listed at 1.7 billion. On Oct. 14, 2026, shares reached a new 52-week low of about $8.38, MarketBeat reported.
Financial measures and business lines
DENTSPLY SIRONA's trailing return on equity was -33.03%. Return on assets was 1.96%. The latest listed balance-sheet figures show total cash of $239 million and total debt to equity of 172.24%. Levered free cash flow was $141.62 million. In the second quarter of 2026, operating cash flow rose to $99 million from $48 million a year earlier. The increase was partly associated with tariff refunds and improved working capital. The supplied data does not provide several valuation ratios, including trailing P/E and price-to-sales.
DENTSPLY SIRONA develops and sells dental equipment and dental products. It also sells healthcare consumables. Its four operating segments are Connected Technology Solutions and Essential Dental Solutions, alongside Orthodontic and Implant Solutions and Wellspect Healthcare. The business covers imaging and digital dentistry, including CEREC and the DS Core platform. It also sells orthodontic and implant products. Wellspect's offerings include medical devices for urinary retention and chronic or severe constipation.
Founded in 1877, the company is headquartered in Charlotte, North Carolina. Its listed estimated earnings date is Nov 5, 2026. DENTSPLY SIRONA maintained its 2026 adjusted EPS outlook of $1.40 to $1.50. Management expected the third quarter to be weaker than the second, with improvement later in the year. The company's Return-to-Growth program focuses on sales and clinical education. It also includes research and development.
On Oct. 8, 2026, DENTSPLY SIRONA obtained lender consent to amend its revolving credit facility, originally entered into on May 12, 2023, with JPMorgan Chase Bank as administrative agent. The amendments raised the maximum Total Leverage Ratio and Senior Leverage Ratio for the quarters ending Sept. 30 and Dec. 31, 2026. They also permitted specified EBITDA adjustments.
The amended terms temporarily restrict certain new liens and subsidiary debt, along with certain payments, until the company provides its compliance certificate for the year ending Dec. 31, 2026, subject to exceptions. The filing covered the revolver and private debt agreements. It also added quarterly reporting on savings programs and related costs. The amendments were disclosed in the company's SEC filings.
